Trial in Arrhythmia Radioablation for Ventricular Tachycardia: Single Fraction vs Three Fractions

Launched by WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY · Dec 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat patients with a heart condition called refractory ventricular tachycardia (VT), which means their heart beats too fast and traditional treatments haven't worked for them. The researchers want to find out if giving a higher dose of treatment in one session is just as safe and effective as spreading the same dose over three sessions. This could help improve treatment options for patients who have not had success with regular medications or procedures.

To join the study, participants need to be at least 18 years old and have specific heart issues, like ischemic or hypertrophic cardiomyopathy, along with a history of severe VT that hasn't responded to other treatments. Participants should be ready to follow study guidelines and attend follow-up appointments for up to three years. If you or a loved one is considering this trial, it’s important to know that it will focus on finding better ways to help those struggling with this challenging heart condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• * Structural heart disease:
• • 1. Ischemic cardiomyopathy
• • 2. Non-ischemic cardiomyopathy
• • 3. Hypertrophic cardiomyopathy
• * Refractory VT severity:
• • 1. VT leading to ICD shock with minimum 3 episodes in any 3-month period without reversible cause;
• • 2. Failed or intolerant to antiarrhythmic drug therapy (either amiodarone or ≥ 2 AADs) AND failed ablation (CA)
• • 3. OR ablation (CA) contraindicated
• • Ability to understand study protocol and to write informed consent
• • Willing to comply with specified pre-, post- and follow-up testing, evaluations and requirements
• • Expected to remain available for at least 36 months after enrollment
• Exclusion Criteria:
• • Age \< 18 years
• • Pregnancy
• • Prior chest radiation therapy